Research Topics
Species | E AnaissieSummaryCountry: USA Publications
| Collaborators
|
Detail Information
Publications
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 yearsA Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 114:600-7. 2001..In conclusion, MEL-140 is less toxic and appears equally as efficacious as MEL-200 in elderly patients. The benefits of tandem SCT in this patient population need further evaluation in a randomized trial...- Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapyM Zangari
Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
Blood 98:1614-5. 2001.... - Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor aloneK R Desikan
The Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 112:242-7. 2001..Patients with high tumour burden, i.e. beta(2)-microglobulin levels > 2.5 mg/l, probably benefit from chemotherapy for mobilization both in terms of cytoreduction and adequate stem cell mobilization resulting in accelerated engraftment... - Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patientsB Barlogie
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 98:492-4. 2001..Response rates were higher and survival was longer especially in high-risk patients given more than 42 g THAL in 3 months (median cumulative dose) (landmark analysis); this supports a THAL dose-response effect in advanced MM... - Transplantation as salvage therapy for high-risk patients with myeloma in relapseC-K Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Bone Marrow Transplant 30:873-8. 2002..001). Their survival at 2 years post-ST was 43%, 17% and 11%, respectively. Our study suggests further transplantation should only be considered in the setting of a clinical trial in patients with favorable prognostic factors... - Results of autologous stem cell transplant in multiple myeloma patients with renal failureA Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 114:822-9. 2001..MEL-140 had an acceptable toxicity and appeared equally effective as MEL-200. In the setting of renal failure, the role of auto-SCT early in the disease course and benefits of tandem SCT require further evaluation... - High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusionsA Badros
Myeloma and Transplantation Research Center and Department of Pathology, University of Arkansas for Medical Sciences and Veterans Health System, Little Rock, USA
Blood 97:2574-9. 2001..Remarkable graft versus myeloma responses were seen in chemotherapy-refractory patients. Two patients died of progressive disease, and 3 died of GVHD complications without active disease. GVHD remains a major problem with this procedure... - Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplantC K Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Bone Marrow Transplant 33:823-8. 2004..05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course... - Thalidomide in the management of multiple myelomaB Barlogie
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Semin Hematol 38:250-9. 2001..The virtual lack of myelosuppression makes it an ideal agent for combination with cytotoxic chemotherapy. Newer, more potent, and less toxic derivatives of thalidomide are being evaluated... - Clinical activity of arsenic trioxide for the treatment of multiple myelomaN C Munshi
University of Arkansas for Medical Sciences, Myeloma and Transplantation Medical Center, Little Rock, AR, USA
Leukemia 16:1835-7. 2002..The results of this small trial support further investigation of this novel drug for the treatment of patients with relapsed or refractory MM... 
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myelomaM Pineda-Roman
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Leukemia 22:1419-27. 2008..The MMSET/FGFR3 molecular subtype was prognostically favorable, a finding since reported for a VTD-incorporating tandem transplant trial (Total Therapy 3) for untreated patients with myeloma (BJH 2008)...- Thalidomide in the management of multiple myelomaB Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
Semin Oncol 28:577-82. 2001..Several trials are currently underway at the Arkansas Myeloma and Transplantation Research Center to determine the clinical benefit of adding thalidomide to post-transplant salvage therapy and in the upfront management of patients... - Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complicationsM Zangari
Central Arkansas Veteran s Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Blood Coagul Fibrinolysis 13:187-92. 2002..In conclusion, in this series, acquired APC resistance was present in almost one-quarter of newly diagnosed myeloma patients and significantly increased the risk of DVT... - 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodesT Mahfouz
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, 72205, USA
J Clin Oncol 23:7857-63. 2005..CONCLUSION: In patients with MM, FDG-PET is a useful tool for diagnosing and managing infections even in the setting of severe immunosuppression... - Suppression of abnormal karyotype predicts superior survival in multiple myelomaV Arzoumanian
Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Leukemia 22:850-5. 2008..35, P=0.044) and relapse (HR=2.47, P<0.001). Collectively, these results underscore the importance of monitoring for CA and attest to the favorable prognostic consequences of CA suppression with effective therapy... - Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantationA B T Fassas
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Leuk Lymphoma 46:1159-61. 2005..A cut-off point of 100 mg/l (CRP levels) and 15 mg/l/day (CRP velocity) identified patients likely to suffer severe complications with 86 and 75% sensitivity, respectively. Prospective validation of this model is currently underway...